BACE1 and Alzheimer disease: Besides a reduced body weight, several BACE1-targeted inhibitors tested in advanced clinical trials induced a mild, non-progressive and reversible cognitive worsening, which is seen as an unacceptable side effect that needs to be understood and defined by predictive biomarkers before BACE inhibitors may be tested in future prevention trials for AD [9].